Latest News & Updates

Biologics Contribute to Growth in Pharma Products Cold-Chain Market

In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...

Wednesday, September 12, 2018 | Read More

FDA Researchers Explore Fundamental Chemical Reaction that Could Threaten the Quality of Therapeutic Protein Products

In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...

Tuesday, September 11, 2018 | Read More

Sentry representatives attend DCAT week

Sentry BioPharma Services is pleased to announce delegates from Sentry’s Business Development team will be in New York City attending the Drug, Chemical & Associated Technologies Association (DCAT) Week March 19th -22nd. The four-day conference brings together key sourcing, procurement and business...

Monday, March 19, 2018 | Read More

Leadership

Tim J. Mitchell, J.D. - President & Chief Executive Officer

Sentry's mission exceeds partnering with our clients. Our focus is to become an integral part of their team, working together to define the best solution possible to meet the ever-changing challenges in the industry today and in the future.

Mr. Tim Mitchell functions as President and Chief Executive Officer for Sentry BioPharma Services, Inc., a wholesaler/third party logistics provider of prescription and investigational drug products, medical devices, and active pharmaceutical ingredients for the pharmaceutical and medical device industry. Mr. Mitchell is principal founder of Sentry and has been at its helm these past eleven (11) years.  As President, he has guided Sentry from inception through start up and onto profitability and mature growth.

Mr. Mitchell is a proven entrepreneur and business leader with more than 35 years of expertise in financial planning and management, investment strategy and business development. His professional accomplishments include a documented track record of helping both new ventures and established organizations attain and maintain profitability. In his role as Chief Executive Officer at Sentry, Mr. Mitchell is responsible for day-to-day management decisions including oversight of all business operations including shipping/receiving, storage, recordkeeping, and quality, and for implementing Sentry’s long and short term plans.  Further, Mr. Mitchell acts as a direct liaison between the Board of Directors and Sentry’s management team.

PROFESSIONAL EXPERIENCE

2005 - Present:                    President and Chief Executive Officer, Sentry BioPharma Services, Inc.

1996 - 2005:                         President, First Capital Investment Group, Inc.

1991 - 1996:                         Private Law Practice

1984 - 1991:                         Vice President & Corporate Counsel, Waterford Investment Corporation

 

EDUCATION

Mr. Mitchell’s educational background and professional experience is in corporate law with an emphasis on contract and taxation law.  Mitchell received a J.D. cum laude and B.A. degrees with honors from Indiana University, Bloomington, Indiana.

 

PROFESSIONAL PARTICIPATION

Mr. Mitchell currently sits on numerous boards of directors, both for profit and not for profit organizations. Other professional memberships include BIO (Biotechnology Innovation Organization), IQPC Supply Chain, Partnerships in Clinical Trials, Pharma Connections Worldwide, BioNetwork, GDP & Temperature Management Global Forum and the Indiana State Bar Association.